ASAngelika Szpulak

Angelika Szpulak

*This is an algorithmically generated author record based on publicly available information.

Angelika Szpulak has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Methods of surfactant administration in newborn. Literature review

    by Julia Głoskowska, Agata Frańczuk, Katarzyna Kuleta, Tomasz Dyl, Adrian Kruk, Hanna Gruszczyńska, Angelika Szpulak, Ewelina Kopczyńska, Aleksandra Makłowicz, Michał Peregrym

    The most common cause of respiratory distress syndrome (RDS) in neonates born prematurely is surfactant deficiency. Surfactant administration has been the method of choice for the treatment of RDS since the 1990s, only the method of delivery is changing with the use of increasingly less invasive methods of respiratory support in neonatal respiratory failure. For many years, the standard method was the administration of surfactant after intubation through an endotracheal tube during artificial ventilation. Gradually, new methods were introduced to reduce or avoid the use of ventilation (INSURE), followed by methods that bypass intubation (LISA). The latest SALSA technique made it possible to omit the use of a laryngoscope and the need for intubation. The new methods of surfactant administration can be used successfully in newborns requiring only non-invasive respiratory support, in neonatal centers in regions with limited access to specialized medical care.

  • Open Access

    Nordic walking – the healthiest sport ever? – A review

    by Angelika Szpulak, Aleksandra Makłowicz, Ewelina Kopczyńska, Agata Frańczuk, Michalina Grzelka, Julia Głoskowska, Katarzyna Kuleta, Katarzyna Słychan, Katarzyna Kuśmierczyk, Patrycja Karkos

    Nordic Walking (NW) is a widely practiced sport that was originally intended as a way for cross-country skiers to get a year-round workout. However, it quickly proved to be easy, enjoyable and undemanding, which led populations around the world to train NW. Today, the sport is used as rehabilitation in most medical specialties, as it is considered to be safe, not creating barriers, inexpensive and has no side effects. This article presents a literature review on the effects of NW on patients' mental and physical health.


  • Open Access

    Rimegepant - a breakthrough drug for migraine treatment - literature review

    by Katarzyna Kuleta, Julia Głoskowska, Agata Frańczuk, Michalina Grzelka, Aleksandra Makłowicz, Ewelina Kopczyńska, Angelika Szpulak, Patrycja Karkos, Katarzyna Kuśmierczyk, Natalia Dolata

    Migraine is a chronic condition that manifests itself periodically. It is characterized by recurrent, severe, often hemiplegic, throbbing headaches accompanied by autonomic symptoms in the form of nausea, vomiting, hypersensitivity to noise and light. For many years, triptans have been the gold standard in the treatment of migraine, acting by constricting blood vessels and inhibiting the release of neuropeptides. However, their efficacy is not satisfactory for all patients, especially those with cardiovascular disease. In response to the need for effective and safe therapies, gepants, a new class of drugs that block the calcitonin gene-related peptide (CGRP) receptor, have emerged. Rimegepant, one of the newest representatives of gepant, has been approved for the treatment of migraine both in the acute attack phase and prophylactically. Clinical trials have shown its effectiveness in reducing the number of days with migraine and alleviating associated symptoms. Rimegepant also has a favorable safety profile, making it a promising therapeutic option for migraine patients. This article aims to discuss in detail rimegepant as a new treatment option for migraine, including its mechanism of action, efficacy, safety profile, clinical trial and outlines the benefits of introducing this drug into standard clinical practice.

  • Open Access

    Advances in migraine treatment - a review

    by Katarzyna Słychan, Agata Frańczuk, Aleksandra Makłowicz, Angelika Szpulak, Ewelina Kopczyńska, Julia Głoskowska, Michalina Grzelka, Katarzyna Kuleta, Aleksandra Elżbieta Łęska, Paulina Kejna

    Introduction Migraine is a heavily debilitating disease that ranks second place in Global Burden Disease. It is estimated that around 1 billion of people suffer from it. It also has a significant negative impact on health-related quality of life (HRQoL) of patients and can affect their social, occupational, academic and familial life. Thus, it is crucial that all of the patients receive an effective treatment. Objectives This article aims to review the most recent advances in treatment of migraine. Methods A Literature review of articles published in Pubmed between 2000 and 2024 using the following words ‘migraine’, ‘treatment advances’, ‘CGRP receptor antagonists’, ‘serotonin receptor agonists’, ‘lasmiditan’, ‘zavegepant’, ‘rimegepant’. Results Literature search provides several concepts of advances in migraine treatment. Apart from behavioral treatment, new drugs targeting calcitonin gene related receptors (CGRP) and serotonin receptors agonists are emerging. Conclusion Migraine is a debilitating disease which significantly reduces health related quality of life in patients. New drugs targeting calcitonin gene related receptors (CGRP) and serotonin receptors agonists give a chance for more effective and tailored treatment.

  • Open Access

    Upadacitinib - New Janus Kinase Inhibitor - Literature Review

    by Michalina Grzelka, Jakub Plizga, Agnieszka Głuszczyk, Aleksandra Makłowicz, Ewelina Kopczyńska, Angelika Szpulak, Agata Frańczuk, Julia Głoskowska, Katarzyna Kuleta, Patrycja Karkos

    Atopic dermatitis (AD) is a chronic, recurrent dermatosis that affects an increasing percentage of the population. It usually affects children and resolves spontaneously, however, symptoms can persist into adulthood and even appear de novo later in life. The skin lesions that appear in this disease significantly reduce patients quality of life. Visual skin symptoms are exacerbated during stress, and pruritus leads to sleep problems. The effect of an inadequately controlled disease can even be a reduction in social activities and a reluctance to leave the house. The basis of treatment is skin care using emollients and avoiding triggers and aggravating factors. In the next stage, the doctor may prescribe topical or systemic treatment for the patient, depending on the severity of the disease. Such measures may not be enough, so more and more new drugs are being registered for the treatment of atopic dermatitis. One of them is upadacitinib, which appears to be extremely effective compared to other medications used to treat moderate to severe ad. It is a selective JAK inhibitor that reduces the inflammatory response by inhibiting migration, proliferation and cytokine secretion by granulocytes. It brings rapid and sustained effects in reducing skin lesions and reducing one of the most bothersome symptoms, pruritus.It may serve as a good alternative to the existing methods for treating moderate to severe atopic dermatitis The purpose of our study is to describe this new drug, its mechanism of action and discuss its possible benefits versus side effects.

  • Open Access

    Bempedoic acid – new agent in hiperlipidemia treatment – literature review

    by Agata Frańczuk, Aleksandra Makłowicz, Jakub Plizga, Agnieszka Głuszczyk, Ewelina Kopczyńska, Angelika Szpulak, Michalina Grzelka, Katarzyna Kuleta, Katarzyna Słychan, Julia Głoskowska

    Hyperlipidemia is becoming more and more severe condition among modern society. High-fat diet, sedentary lifestyle, lack of physical activity are the common factors leading to overweight, obesity and problems with serum lipid control. Dyslipidemia is one of the most important agents contributing to cardiovascular diseases snd therefore lower quality of life, disability and preamature death. This forces to constatnt searching for lipid-lowering drugs, that can be successfully use in the patients suffering from poor lipid control. Bempedoic acid (ETC-1020) is one of the newest, first in the class medicine, firstly approved to use in the USA on 21st February 2020 in monotheraphy, and then on 26th February in combination with ezetimibe. It is a small synthetic prodrug molecule that is activated by acyl-CoA synthetase in the liver. Bempedoic acid inhibits competitively adenosine triphosphate citrate lyase (ACL) and as a result it stops the further production of cholesterol and fatty acids. Research shows the ability of ETC-1020 to decline of LDL-C cholesterol up to 24%. It is also responsible for total cholesterol, non-HDL-C, ApoB and hs-CRP reduction. Bempedoic acid is characterized by good pharmacokinetics and pharmacodynamics. ECT-1020 has also a good drug-to-drug interaction profile. Many clinical trials have reported efficacy and safety of use with minimal side effects. Because of its target point is located in the liver and kidney, it can be successfully use in patients with statin intolerance due to bypassing decline of muscle cholesterol biosyntheisis, that is the main cause of musculosketelar adverse effects.


  • Open Access

    Danuglipron – an innovate GLP agonist - literature short review

    by Agata Frańczuk, Angelika Szpulak, Ewelina Kopczyńska, Aleksandra Makłowicz, Katarzyna Kuleta, Julia Głoskowska, Michalina Grzelka, Katarzyna Słychan, Agnieszka Głuszczyk, Jakub Plizga

    Obesity and type 2 diabetes mellitus (T2DM) are global health problems with increasing prevalence, associated with numerous metabolic, cardiovascular and renal complications(1,2). Current treatments include GLP-1 receptor agonists (GLP-1RAs), which have shown benefits in weight reduction and glycaemic control. Danuglipron, a novel, oral, small-molecule GLP-1RA, is being investigated for its efficacy in treating these conditions. The novel oral method of administration may contribute to an increase in its regularity of use among patients who find systematic use of injections difficult. The aim of our study is to describe this new drug, its' mechanism of action and discuss possible benefits versus adverse effects. Obesity and type 2 diabetes mellitus (T2DM) represent significant global health challenges with a rising prevalence, linked to a multitude of metabolic, cardiovascular, and renal complications. Current therapeutic approaches encompass GLP-1 receptor agonists (GLP-1RAs), which have exhibited favorable outcomes in weight management and glycemic regulation. Danuglipron, an innovative oral small-molecule GLP-1RA, is undergoing investigation for its effectiveness in addressing these conditions. The unique oral delivery method could potentially enhance its adherence among patients encountering difficulties with routine injections. Our study aims to delineate this novel medication, elucidate its mechanism of action, and deliberate on the prospective benefits versus drawbacks.

  • Open Access

    Challenges and risks of using GLP-1 antagonists in treating type 2 diabetes and obesity

    by Agnieszka Głuszczyk, Jakub Plizga, Aleksandra Makłowicz, Ewelina Kopczyńska, Angelika Szpulak, Agata Frańczuk, Michalina Grzelka, Julia Głoskowska, Katarzyna Kuleta, Patrycja Karkos

    Introduction: Ozempic (semaglutide) is a long-acting GLP-1 receptor agonist widely used to treat type II diabetes and obesity. Its mechanism of action includes stimulation of insulin secretion, inhibition of glucagon secretion, and delaying gastric emptying, which leads to lower blood glucose levels and body weight reduction. Despite its therapeutic benefits, the use of Ozempic may cause side effects that affect patients' quality of life and their ability to continue treatment. This article aims to comprehensively analyze side effects associated with using Ozempic to provide a detailed understanding of their development mechanisms and their impact on patient's daily functioning.Material and Methods of Research: The literature was collected through searches in the PubMed and Google Scholar databases and references from the initially retrieved articles. Results: The literature review indicates various potential side effects of liraglutide, including gastrointestinal upset, pancreatitis, and the 'Ozempic face' phenomenon. This phenomenon, characterized by a skeletal facial appearance with deepened wrinkles, may result from the drug's impact on body composition and fat distribution, leading to a loss of subcutaneous fat in the face and a more pronounced appearance of underlying facial structures.Conclusion: Clinical studies highlight the need for continuous patient monitoring by healthcare providers to ensure the safe and effective use of Ozempic. Further education on a healthy lifestyle, diet, and physical activity is necessary to maintain the effects of drug therapy and prevent weight gain after treatment. Additional research on the long-term safety of GLP-1 is also crucial. Physicians should be aware of the potential risks and side effects associated with the use of Ozempic and should educate their patients to enable them to make informed decisions about their treatment.


  • Open Access

    Impact of E-Cigarettes and Tobacco Heating Systems on Health: A Review of Current Research

    by Jakub Plizga, Agnieszka Głuszczyk, Aleksandra Makłowicz, Ewelina Kopczyńska, Angelika Szpulak, Agata Frańczuk, Michalina Grzelka, Julia Głoskowska, Katarzyna Kuleta, Katarzyna Słychan

    Introduction: The growing popularity of e-cigarettes (EC) and tobacco heating systems (THS) raises concerns about their impact on the health of users and passive smokers. These products are attractive to young people due to their lack of unpleasant odor and easy availability, even though they contain addictive nicotine and harmful substances. Materialtrial and Methods of Research: China's first e-cigarette was developed in 2003. The WHO, a leading global health organization, has been actively involved in regulating the advertising and use of EC. They initially allowed the advertising of EC as a healthier cigarette alternative but later banned it due to a lack of scientific evidence. In Poland, the sale of EC to persons under 18 is prohibited, but this law needs to be better enforced. ECs heat a liquid containing nicotine, creating an aerosol with toxic substances such as acetone, glycerol, acrolein, and formaldehyde. Studies show that EC use leads to adverse health effects such as headaches, nausea, contact allergies, increased blood pressure, irregular heart rhythm, thrombosis, and cancer risk. ECs also affect oral health and the respiratory system, increasing the risk of asthma and chronic obstructive pulmonary disease (COPD). THS, introduced in 2019, heats tobacco to 300°C, producing an aerosol containing carcinogenic and toxic substances. These products negatively affect the cardiovascular and respiratory systems, increasing the number of pro-inflammatory cells in the lungs and potentially producing hepatotoxic effects. Conclusion: The increasing use of EC and THS among adolescents raises serious health concerns. These products, although perceived as less harmful, contain toxic substances and addictive nicotine. Further research is needed on their long-term effects to increase patient awareness and limit the availability of these products to minors.

  • Open Access

    Does a Healthy Diet Have a Protective Effect on the Development of Depression? – A Review Article

    by Hanna Ćwirko, Angelika Szpulak, Urszula Garlak, Giuseppe Mirabella, Karolina Mikołajczak

    Background: Depressive disorder is one of the most common mental disorders all over the world experienced by 3.8% of the world’s population, including 5% of adults and 5.7% of adults over 60 years old. Depression can be characterized by various symptoms like depressed mode, loss of interest, weight loss or gain, feeling worthless, or excessive guilt. Studies show that depression risk factors may be lowered by following a healthy diet, like the Mediterranean diet, consumption of fish and vegetables, vitamin D 3 , probiotics, or antioxidants. Objectives: The purpose of this paper was to summarize known factors with protective effect on the development of depression and possible intervention in daily habits of patients who are suffering from the disorder. Material and Methods: The conclusions of the article were formulated by analysing the available literature mostly from 2019–2024 in PubMed and Google Scholar database. The articles were selected based on the following search criteria in various combinations: “depression”, “diet”, “antioxidants”, “gut microbiota”, “Mediterranean diet”, “omega -3”, “vitamin D”. 120 articles were considered, where 40 references were chosen and 80 rejected. The selection of articles was conducted according to the subject of the review paper and appropriate search criteria. Results: In controlled studies, patients with diagnosed major depressive disorder were reported to have low levels of bacteria representing intestinal gut microbiota, vitamin D 3 , and omega -3 acids. Following the Mediterranean diet, full of vegetables, fruits, nuts, whole grains, and olive oil as a main source of dietary fats, patients were reported to have reduced symptoms of depression and anxiety. A correlation was shown between the imbalance of oxidative stress and the antioxidant defence and depressive disorders. Conclusions: The findings suggest a strong connection between healthy lifestyle, dietary intervention and development of a depressive disorder.